MRI Research Shows ‘Virtually Complete Abrogation’ of New Lesions with Switch to Ofatumumab for Multiple Sclerosis Patients

MRI Research Shows ‘Virtually Complete Abrogation’ of New Lesions with Switch to Ofatumumab for Multiple Sclerosis Patients

For patients with relapsing multiple sclerosis, switching from oral therapies to subcutaneous monthly administration of the anti-CD20 monoclonal antibody ofatumumab led to over a 98 percent reduction of Gd+ T1 lesions on MRI at 96 weeks.